2179222-27-4
Chemical Structure
ISTH0036
- CAS No.: 2179222-27-4
- Formula:N/A
- Molecular Weight:N/A
InChIKey: PIRAIAFWMRLCLM-FHLPKGGPSA-N
SMILES: [ISTH0036]
Biological Activity: ISTH0036 is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ISTH0036 | 96.85% | ISTH0036 is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Pfeiffer N, Voykov B, Renieri G, et al. First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery. PLoS One. 2017;12(11):e0188899. [Content Brief]
- [2]. Ruckert R, et al. Long-term safety and efficacy of ISTH0036 - a selective TGF-β2 blocking antisense oligonucleotide in preclinical and Phase 1 clinical studies. Invest Ophthalmol Vis Sci. 2021 Jun;62(8):321.
- [3]. Janicot M. Selective Antisense Oligonucleotide Targeting Transforming Growth Factor beta 2 (TGF-β2) Isoform, in Different Ocular Disease Preclinical Models. Invest Ophthalmol Vis Sci. 2015 Jun;56(7):1278.
